NCT00460460

Brief Summary

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Trial Health

60
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P75+ for phase_1 lymphoma

Timeline
Completed

Started Mar 2007

Shorter than P25 for phase_1 lymphoma

Geographic Reach
2 countries

3 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 12, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 16, 2007

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2007

Completed
Last Updated

January 25, 2011

Status Verified

January 1, 2011

First QC Date

April 12, 2007

Last Update Submit

January 24, 2011

Conditions

Lymphoma

Keywords

Phase IcancerlymphomaleukemiamyelomaAMLALLNHLMM

Interventions

AZD4877DRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with AML, a certain type of ALL, NHL and MM
  • certain types of cancer of the lymph nodes
  • certain types of leukemias (blood cancers)
  • disease has or will fail with other treatments
  • relatively good overall health other than your cancer

You may not qualify if:

  • poor bone marrow function (not producing enough blood cells)
  • serious heart conditions
  • poor liver or kidney function

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Research site

Buffalo, New York, United States

Location

Research Site

New York, New York, United States

Location

Research Site

Toronto, Ontario, Canada

Location

MeSH Terms

Conditions

LymphomaNeoplasmsLeukemiaNeoplasms, Plasma Cell

Interventions

N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesHematologic Diseases

Study Officials

  • Judith Ochs, MD

    AstraZeneca

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

April 12, 2007

First Posted

April 16, 2007

Study Start

March 1, 2007

Study Completion

August 1, 2007

Last Updated

January 25, 2011

Record last verified: 2011-01

Locations

US(2)CA(1)